Topas Announces Positive Results For TPM502 In Celiac Disease
15 Oct 2024 //
BUSINESSWIRE
Topas Therapeutics Appoints Hugo Fry as CEO
07 May 2024 //
BUSINESSWIRE
Topas launches Phase IIa trial of celiac disease therapy
26 May 2023 //
CLINICAL TRIALS ARENA
Topas Therapeutics Initiates Phase 2a Trial for TPM502 in Celiac Disease
25 May 2023 //
BUSINESSWIRE
Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer
14 Feb 2022 //
ACCESSWIRE